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BACKGROUND: Colorectal cancer (CRC) risk varies by race and sex. This study, 1 of 2 microsimulation analyses to inform the 2018
American Cancer Society CRC screening guideline, explored the influence of race and sex on optimal CRC screening strategies.
METHODS: Two Cancer Intervention and Surveillance Modeling Network microsimulation models, informed by US incidence data,
were used to evaluate a variety of screening methods, ages to start and stop, and intervals for 4 demographic subgroups (black and
white males and females) under 2 scenarios for the projected lifetime CRC risk for 40-year-olds: 1) assuming that risk had remained
stable since the early screening era and 2) assuming that risk had increased proportionally to observed incidence trends under the
age of 40 years. Model-based screening recommendations were based on the predicted level of benefit (life-years gained) and bur-
den (required number of colonoscopies), the incremental burden-to-benefit ratio, and the relative efficiency in comparison with strat-
egies with similar burdens. RESULTS: When lifetime CRC risk was assumed to be stable over time, the models differed in the
recommended age to start screening for whites (45 vs 50 years) but consistently recommended screening from the age of 45 years
for blacks. When CRC risk was assumed to be increased, the models recommended starting at the age of 45 years, regardless of race
and sex. Strategies recommended under both scenarios included colonoscopy every 10 or 15 years, annual fecal immunochemical
testing, and computed tomographic colonography every 5 years through the age of 75 years. CONCLUSIONS: Microsimulation model-
ing suggests that CRC screening should be considered from the age of 45 years for blacks and for whites if the lifetime risk has
increased proportionally to the incidence for younger adults. Cancer 2018;000:000-000. VC 2018 The Authors. Cancer published by
Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is prop-
erly cited, the use is non-commercial and no modifications or adaptations are made.
KEYWORDS: colorectal neoplasms, decision modeling, early detection of cancer, guidelines, personalized medicine.
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States.1 Screening can prevent death
from CRC and has been promoted by multiple organizations since 1980.2,3 Recommendations for screening have evolved
over the years, with the emergence of new screening technologies, new evidence on the performance of various screening
methods, and evidence of differential risk across population subgroups.
It has been well documented that individuals with African ancestry have higher rates of CRC incidence and mortality
than individuals of other races or ethnicities in the United States and that men are at higher risk than women.1 Similarly,
longevity varies by race and sex.4 These differences in cause-specific and other-cause mortality could influence the optimal
start age, duration, and intensity of screening.5 A higher risk of CRC may justify a more intensive screening approach,
whereas a high risk of other-cause morbidity and mortality may reduce the benefit from screening at older ages.
There are differences in the current US guidelines for the age to start CRC screening in African Americans. Currently,
the American College of Gastroenterology and the US Multi-Society Task Force recommend that African Americans begin
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screening at the age of 45 years, whereas those of other races
should begin at the age of 50 years, regardless of sex.6,7 The
US Preventive Services Task Force (USPSTF) updated its
screening recommendations for the US general population
in 2016.8 Although it acknowledged that black and Alaska
Native individuals have higher CRC incidence and mortal-
ity rates than the general population and that microsimula-
tion analyses indicated that there may be some merit to
starting screening at the age of 45 years rather than 50 years
even for the general population, it concluded that the cur-
rent evidence best supports a starting age of 50 years for all
individuals at average risk.
To inform the update of its 2008 CRC screening
guideline,9 the American Cancer Society requested a
decision-analytic modeling analysis to further explore the
question of optimal CRC screening strategies by race and sex.
An accompanying article by Peterse et al10 shows that based
on increasing CRC rates in young birth cohorts, modeling
supports earlier screening for the whole population. How-
ever, as explained in that article, there is controversy around
the mechanism for that increase, with some arguing that it is
a detection bias attributable to early uptake of screening
rather than a true increase in risk.11 In this article, we explore
the potential benefit and burden from earlier screening for
black men and women versus whites, and we consider 2 sce-
narios for current background CRC risk: one based on origi-
nal models informed by data from a period before screening
was widely adopted that assumed stable risk and another
based on increasing risk as described by Peterse et al.
MATERIALS AND METHODS
Four US demographic subgroups were distinguished: white
females, black females, white males, and black males. There
were insufficient data to include other races or to distin-
guish Hispanic ethnicity. Two independently developed
microsimulation models for CRC were used to evaluate a
large number of possible screening strategies with various
screening modalities, ages to begin, ages to end, and screen-
ing intervals for each subgroup. Models were developed
within the National Cancer Institute–funded Cancer Inter-
vention and Surveillance Modeling Network. Apart from
the distinction of race- and sex-specific population sub-
groups and scenarios considered for current CRC risk, the
analyses were similar to those performed to inform
USPSTF guideline recommendations (see Supporting
Table 1 for a summary of all differences).12,13
Model Description
The Microsimulation Screening Analysis–Colon (MIS-
CAN-Colon) and the Simulation Model of Colorectal
Cancer (SimCRC) have been described extensively in other
studies14 and in the Cancer Intervention and Surveillance
Modeling Networkmodel registry.15 Eachmodel consists of
3 components, which are used to simulate individual life his-
tories from birth to death under alternative CRC screening
strategies. First, the demography component determines
each simulated person’s date of birth and death in the
absence of CRC. Second, the natural history component is
used to simulate the potential development of CRC and
reductions in the overall years of life. The natural history of
CRC is assumed to follow the adenoma-carcinoma sequence
(Supporting Fig. 1). Simulated individuals may develop 1 or
more adenomas. An adenoma may grow in size and develop
into CRC, which then may transition through stages I to IV
without symptoms or be clinically diagnosed at any stage.
Depending on the varying rates of CRC progression and
survival, simulated individuals may die of either other causes
or clinically diagnosed CRC. The third component, the
model’s screening component, allows a simulated person’s
life trajectory to be altered because of the detection of pre-
clinical CRC or the detection and removal of an adenoma.
The demography component was informed by all-
cause mortality rates from the 2013 US life tables by race and
sex.4 For the natural history component, the age-specific ade-
noma onset was based on the prevalence and multiplicity of
adenomas as observed in autopsy studies.16-25 Race- and sex-
specific CRC incidence by age, stage, and localization was cal-
ibrated to data from the Surveillance, Epidemiology, and
End Results Program (SEER) from the period before screen-
ing was widely adopted26: SimCRC was calibrated to 1975-
1979 data, a period devoid of screening, and MISCAN-
Colon was calibrated to 1990-1994 data, a period with lim-
ited screening butmore pronounced racial disparities in CRC
risk (see Supporting Fig. 2 for a comparison of incidence by
period). Race- and sex-specific CRC survival in both models
was based on recent SEER data.27 The screening component
was informed by data on the sensitivity and specificity of the
test performed and, for endoscopic tests, the proportion visu-
alizing the complete colon or rectum (Table 1).
The models have been validated against the mortality
reductions of the UK Flexible Sigmoidoscopy Screening
(UKFSS) trial of once only sigmoidoscopy.31 The
MISCAN-Colon model has also been validated in the Nor-
wegian Colorectal Cancer Prevention (NORCCAP) trial32
and the Screening for Colon and Rectum (SCORE) trial.33
Study Population
For each of the 4 population subgroups described previ-
ously, the models simulated outcomes for 40-year-old
individuals without a prior CRC diagnosis.
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Scenarios for Background Risk
Two scenarios were considered for the projected lifetime
risk of CRC in 40-year-olds in the absence of screening. In
the first scenario, the conventional scenario in microsimu-
lation models for CRC screening,12,13 age-specific risks of
CRC were assumed to have remained at the level observed
before screening was widely adopted in the United States.
In the second scenario, age-specific CRC risks for all ages
older than 40 years were assumed to have increased propor-
tionally to observed trends in incidence for individuals
TABLE 2. Screening Strategies Evaluated by the Model for Each Race and Sex Subgroupa
Screening Modality
Age to Begin
Screening, y
Age to
End Screening, y
Screening
Interval, y
No. of Strategies
(Unique)b
No screening 1
Stool-based screening
FIT 45, 50, 55 75, 80, 85 1, 2, 3 27 (27)
HSgFOBT 45, 50, 55 75, 80, 85 1, 2, 3 27 (27)
FIT-DNA 45, 50, 55 75, 80, 85 1, 3, 5 27 (27)
SIG screening 45, 50, 55 75, 80, 85 5, 10 18 (15)
CTC screening 45, 50, 55 75, 80, 85 5, 10 18 (15)
Colonoscopy screening 45, 50, 55 75, 80, 85 5, 10, 15 27 (20)
Total No. of (unique) screening
strategies evaluated in the
model
145 (132)
Abbreviations: CTC, computed tomographic colonography; FIT, fecal immunochemical testing; FIT-DNA, fecal immunochemical testing with a DNA stool test
(multitarget stool DNA testing); HSgFOBT, high-sensitivity guaiac-based fecal occult blood testing; SIG, flexible sigmoidoscopy.
a Strategies were similar to those evaluated in an analysis for the US Preventive Services Task Force.13 Combinations of SIG with stool-based screening were
not considered here.
b The number of unique strategies excludes the strategies that result in the same screening regimen (eg, colonoscopy every 10 years from the ages of 50-80 years and
colonoscopy every 10 years from the ages of 50-85 years both include colonoscopies at the ages of 50, 60, 70, and 80 years and thus are not unique strategies).
TABLE 1. Screening Test Characteristics Used in the Analysisa
Test Characteristic
Colonoscopy (per Lesion
Within Reach)b
FIT
(per Person)
HSgFOBT
(per Person)
FIT-DNA
(per Person)
SIG (per Lesion
Within Reach)
CTC
(per Lesion)
Sensitivity for adenomas  5 mm, % 75 (70-79) 7.6 (6.7-8.6)c 7.5 (7.5-7.5)d 17.2 (15.9-18.6)c 75 (70-79) —
Sensitivity for adenomas of 6-9 mm, % 85 (80-92) 12.4 (10-26.2) 85 (80-92) 57 (48.9-71.6)
Sensitivity for adenomas  10 mm, % 95 (93.1-99.5) 23.8 (20.8-27)e 23.9 (17.7-49.4) 42.4 (38.7-46.2)e 95 (93.1-99.5) 84 (75.6-92.4)
Sensitivity for CRC, % 95 (93.1-99.5) 73.8 (62.3-83.3) 70 (61.5-79.4) 92.3 (84-97) 95 (93.1-99.5) 84 (75.6-92.4)
Specificity, % 86f 96.4 92.5 89.8 87f 88g
Proportion completed, % 95h 100 100 100 76h 100
Risk of fatal complications, % 0.01i 0 0 0 0i 0
Abbreviations: CRC, colorectal cancer; CTC, computed tomographic colonography; FIT, fecal immunochemical testing with a positivity cutoff of 100 ng of
hemoglobin/mL of buffer (20 lg of hemoglobin/g of feces); FIT-DNA, fecal immunochemical testing with a DNA stool test (multitarget stool DNA testing);
HSgFOBT, high-sensitivity guaiac-based fecal occult blood testing; SIG, flexible sigmoidoscopy
The ranges evaluated in the sensitivity analysis are presented in parentheses after the base-case characteristics.
a Test characteristics were similar to those used in an analysis for the US Preventive Services Task Force13.
b It was assumed that the same test characteristics for screening colonoscopies applied to colonoscopies for diagnostic follow-up or for surveillance.
c For individuals with 1- to 5-mm adenomas, it was assumed that the sensitivity was equal to the positivity rate in individuals without adenomas. The sensitivity
for individuals with 6- to 9-mm adenomas was such that the weighted average sensitivity for individuals with 1- to 9-mm adenomas equaled that for nonad-
vanced adenomas.
d It was assumed that 1- to 5-mm adenomas did not bleed and, therefore, could not cause a positive stool test. It was also assumed that HSgFOBT could be
positive because of bleeding from other causes, the probability of which was equal to the positivity rate in individuals without adenomas.
e Sensitivity for individuals with advanced adenomas (ie, adenomas  10 mm or adenomas with advanced histology). Sensitivity was not reported for the sub-
set of individuals with 10-mm adenomas.
f The lack of specificity with endoscopy reflects the detection of nonadenomatous polyps, which, in the case of sigmoidoscopy, may lead to unnecessary diagnos-
tic colonoscopy and, in the case of colonoscopy, leads to unnecessary polypectomy, which is associated with an increased risk of colonoscopy complications.
g The lack of specificity with CTC reflects the detection of 6-mm nonadenomatous lesions, artifacts, stool, and adenomas smaller than the 6-mm threshold
for referral to colonoscopy that are measured as 6 mm.
hWith colonoscopy, 95% reached the end of the colorectum (cecum); for the remaining 5%, the endpoint was distributed between the cecum and the rectum.
With SIG, 76% reached the end of the sigmoid colon; 14% had an endpoint between the beginning and the end of the sigmoid colon; and 12% had an end-
point between the beginning and end of the descending colon.
i The risk of complications is conditional on polypectomy. Case fatality was derived as the combination of the overall perforation rate from Warren et al28 and
the mortality given perforation (0.0519) from Gatto et al.29,30 Sigmoidoscopy was modeled without biopsy or polypectomy of detected lesions and was, there-
fore, assumed to have a 0 mortality risk.
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younger than 40 years old.34 Hence, the assumed relative
increase in lifetime risk across models was 1.80 to 1.90 for
white females, 1.24 to 1.27 for black females, 2.07 to 2.13
for white males, and 1.41 to 1.56 for black males. The
increase was assumed to have arisen from an increased rate
of adenoma onset, primarily in the rectum and distal colon.
More details on the background andmethodology for these
assumptions are in the article by Peterse et al.10
Screening Strategies
Six screening modalities were evaluated: colonoscopy, fecal
immunochemical testing (FIT) with a positivity cutoff at
hemoglobin levels  20 lg/g of stool, high-sensitivity
guaiac-based fecal occult blood testing (HSgFOBT), mul-
titarget stool DNA testing (fecal immunochemical testing
with a DNA stool test [FIT-DNA]), flexible sigmoidos-
copy (SIG), and computed tomographic colonography
(CTC). For each modality, multiple ages to begin and
end screening and multiple screening intervals were evalu-
ated for a total of 132 unique strategies for each popula-
tion subgroup or 528 across all race and sex combinations
(Table 2). In all evaluated strategies, individuals in whom
adenomas were detected and removed received colonos-
copy surveillance through the age of 85 years. It was
assumed that there was 100% adherence to all procedures
to avoid compensation of lower adherence rates by shorter
recommended screening intervals. As a result, predicted
outcomes from the model reflect the potential lifetime
benefits and burden of screening with the assumption of
full adherence to the entire screening process.
Main Outcomes
The benefit or effectiveness of screening was measured by
the number of life-years gained (LYG) from the screening
strategy; this accounted for life-years lost because of fatal
screening complications. The primary fatal complication is
perforation of the colon, which occurs at a rate less than 1
per 1000 colonoscopies; approximately 5% of these cases
result in death.35,36 The number of required colonoscopies
was used as a measure of the aggregate burden of screening,
and it included colonoscopies for screening, follow-up, sur-
veillance, and the diagnosis of symptomatic cancer. We con-
trolled for the burden of tests other than colonoscopy by
grouping and comparing tests with similar noncolonoscopy
burdens. This resulted in 4 classes of screening modalities:
colonoscopy, stool-basedmodalities, SIG, andCTC.
Analysis
Efficient and near-efficient screening strategies
Efficient strategies were identified via the plotting of LYG
with respect to the number of required colonoscopies. A
strategy was considered efficient when it provided the larg-
est incremental increase in LYG per additional colonoscopy
performed in comparison with the next less colonoscopy-
intensive screening strategy within the same class of screen-
ing modalities. The line connecting all efficient strategies is
the efficient frontier. Near-efficient strategies were defined
as strategies just below the efficient frontier that provided at
least 98% of the maximum incremental benefit per addi-
tional colonoscopy performed in comparison with the next
less effective strategy on the efficient frontier. For efficient
and near-efficient screening strategies, the incremental
number of colonoscopies (DCOL), the incremental num-
ber of life-years gained (DLYG), and the burden-to-benefit
ratio (or efficiency ratio [ER]: DCOL/DLYG) in compari-
son with the next less effective strategy on the efficient fron-
tier were calculated.
Model recommendations
Model-recommendable strategies fulfilled 3 main criteria:
efficiency within their class of screening modality,
Figure 1. Illustration of the selection algorithm for model-
recommendable strategies. Each dot represents the hypo-
thetical outcome for a single screening strategy. The bold line
is the efficient frontier connecting efficient strategies (not
plotted as separate dots). Dashed lines represent thresholds
imposed by the decision algorithm: the efficiency criterion
ensures that recommended strategies are efficient in terms
of the yield in LYG for any level of COL requirement, the ben-
efit criterion ensures that LYG do not lag far behind a
selected reference strategy, and the burden-to-benefit crite-
rion ensures that the incremental number of required COLs
per LYG does not exceed a predefined number. The shaded
area encompasses strategies fulfilling all 3 decision criteria.
The model-recommended strategy is the strategy within this
area with the highest predicted number of LYG. COL indi-
cates colonoscopy; LYG, life-years gained.
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comparable overall benefit as measured by LYG, and an
acceptable balance of burden and benefit (see Fig. 1).13
First, an optimal colonoscopy screening strategy was
selected. This was an efficient or near-efficient colonos-
copy screening strategy required to provide at least as
many LYG as the current general population recommen-
dation of screening colonoscopy (every 10 years between
50 and 75 years) and to have a burden-to-benefit ratio of
no more than 50 additional colonoscopies per LYG. This
threshold was similar to the accepted balance in USPSTF
model recommendations across models13 and was judged
to be an acceptable balance for this analysis by the Ameri-
can Cancer Society. The most effective colonoscopy strat-
egy (defined by most LYG) meeting these requirements
was recommended. Second, for each alternative class of
screening modalities, all strategies with the same ages to
begin and end screening as the optimal colonoscopy strat-
egy (benchmark strategy) were identified, and within-class
efficiency was re-assessed. Model-recommendable strate-
gies were efficient or near-efficient strategies with at least
90% of the LYG of the benchmark colonoscopy strategy
and with a burden-to-benefit ratio lower than the bench-
mark. Again, the most effective strategies within each class
meeting the requirements were considered model-
recommendable. It was possible to have no recommend-
able strategy within a class of screening modalities.
Sensitivity analysis
In sensitivity analyses, 3 alternative scenarios were evalu-
ated. First, we evaluated best-case and worst-case scenarios
for the sensitivity of each evaluated screening modality,
including potential follow-up or surveillance colonoscopy,
to reflect uncertainty in the estimates of the diagnostic per-
formance of each modality (Table 1). Second, we varied
the minimum acceptance threshold for LYG to 75%
instead of 90% for alternative screening strategies in com-
parison with colonoscopy screening. Third, we lowered the
acceptance threshold for burden to benefit from 50 addi-
tional colonoscopies per LYG to 40. For each alternative
scenario, model recommendations were re-assessed.
RESULTS
In the absence of screening, the model-predicted life expec-
tancy and CRC risk among 40-year-olds varied by race
and sex. Life expectancy from the age of 40 years ranged
from 35.3 to 42.3 years in the scenario of stable CRC risk
and was lowest for black males and highest for white
females (Supporting Table 2). In the conservative scenario
of stable background CRC risk, the predicted lifetime
CRC risk ranged from 59.3 to 70.7 per 1000 adults across
population subgroups in MISCAN-Colon and from 58.7
to 78.6 per 1000 adults in SimCRC. In the scenario of
increased CRC risk, predicted lifetime risk across popula-
tion subgroups increased to 76.7 to 149.0 in MISCAN-
Colon and to 79.9 to 162.5 in SimCRC. The predicted
risk was highest for white males, but the rank order for
other demographic subgroups differed across models and
scenarios and in comparison with life-years lost to CRC;
this reflected differences in incidence by age in the data
used to inform each model (Supporting Fig. 2).
Screening Benefit and Burden
Screening was predicted to result in clinically significant
LYG in comparison with no screening by both models,
regardless of the population subgroup and scenario for
CRC risk.
In the scenario of stable age-specific CRC risk, pre-
dicted LYG across models, strategies, and population sub-
groups ranged from 117 to 348 per 1000 adults
(Supporting Tables 3-6). The burden of screening, as
measured by the lifetime number of required colonosco-
pies, varied from fewer than 800 per 1000 adults for trien-
nial FIT during the ages of 55 to 75 years to almost 8000
per 1000 adults for colonoscopy every 5 years during the
ages of 45 to 85 years. The predicted benefit of screening
varied across population subgroups and was higher in
SimCRC than MISCAN-Colon. In MISCAN-Colon,
black females had the highest benefit from any of the
screening strategies (range, 159-306 LYG per 1000
adults), white females had the lowest benefit (117-223
LYG), and white males and black males had similar inter-
mediate benefits (141-258 and 149-284 LYG, respec-
tively). In SimCRC, in contrast, black females and white
males had the highest benefit from screening (175-348
and 194-334 LYG per 1000 40-year-olds, respectively),
white females had somewhat fewer LYG (168-307 LYG),
and black males had the lowest benefit from screening
(142-272 LYG). In general, the lifetime number of colo-
noscopies required for screening was somewhat lower for
black males and females because of their lower life expec-
tancy in comparison with their white counterparts.
In the scenario with increased age-specific CRC risk,
the predicted benefit from screening was substantially
higher than that in the scenario of stable risk, with LYG
ranging from 203 to 556 per 1000 adults in MISCAN-
Colon and from 211 to 673 per 1000 adults in SimCRC;
the maximum benefit from screening thus exceeded 0.5
LYG per individual in both models (Supporting Tables 3-
6). The required number of colonoscopies was only mod-
erately higher for most colonoscopy-based strategies in
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Figure 2. Lifetime number of colonoscopies and LYG for colonoscopy screening strategies under 2 scenarios for CRC risk by model
and demographic subgroup. Colors reflect the screening interval (blue, 15 years; pink, 10 years; green, 5 years), symbols reflect the
starting age (diamonds, 55 years; circles, 50 years; squares, 45 years), and the filling of the symbols reflects the end age (empty, 75
years; crossed, 80 years; and full, 85 years). Efficient and near-efficient strategies are labeled, with efficiency assessed among all
evaluated colonoscopy-based screening strategies. In the stable-risk scenario, the risk within each age-, race-, and sex-specific
demographic subgroup was assumed to have remained stable over time since the early screening phase in the United States (1975-
1979 for SimCRC and 1990-1994 for MISCAN). In the increased-risk scenario, the CRC risk was increased proportionally to observed
trends in CRC incidence among adults younger than 40 years. Estimated incidence rate ratios were 1.80 to 1.90 for white females
(range across models), 1.24 to 1.27 for black females, 2.07 to 2.13 for white males, and 1.41 to 1.56 for black males. CRC indicates colo-
rectal cancer; LYG, life-years gained; MISCAN, Microsimulation Screening Analysis; SimCRC, Simulation Model of Colorectal Cancer.
Figure 2. (Continued)
Modeling CRC Screening by Race and Sex/Meester et al
Cancer Month 00, 2018 7
comparison with the scenario of stable risk and ranged
from 684 to 8024 per 1000 adults across models, strate-
gies, and population subgroups.
Efficient and Near-Efficient Strategies
The set of strategies constituting the efficient frontier was
similar across demographic subgroups and scenarios for
CRC risk but differed between models (Fig. 2, Support-
ing Figs. 3-5, and Supporting Tables 3-6). In general, the
predicted LYG range across evaluated strategies was
smaller in MISCAN-Colon than SimCRC, and this
resulted in a wider set of strategies considered near-
efficient. The incremental burden-to-benefit ratio across
models and population subgroups ranged from 6.0 to
2032.9 from the least to most resource-intensive colonos-
copy-based screening strategy in the scenario of stable
CRC risk. The biggest increase in LYG per additional
screening colonoscopy was derived from lowering the
starting age for screening, with lower resulting ERs for
blacks versus whites in MISCAN-Colon. The previously
recommended strategy of colonoscopy every 10 years
between the ages of 50 and 75 years was among the effi-
cient strategies for all population subgroups in MISCAN-
Colon (range of ERs, 37.7-43.2) but was less efficient in
SimCRC than colonoscopy every 15 years between the
ages of 45 and 75 years (range of ERs, 24.4-31.6). For
strategies other than colonoscopy-based screening, the
range of ERs across models, strategies, and population
subgroups was smaller (2.0-149.8). Among the stool-
based testing strategies, FIT screening was more efficient
than most HSgFOBT and FIT-DNA strategies, regardless
of race and sex.
Compared with the scenario of stable CRC risk, the
scenario of increased CRC risk was predicted to result in
lower ERs because of increased LYG from screening; a
smaller total ER range across models, evaluated strategies,
and population subgroups (0.1-992.8); and a further
expanded set of near-efficient strategies inMISCAN-Colon.
Model-Recommendable Strategies
In the scenario of stable age-specific CRC risk, the 2 mod-
els differed in their recommended ages to start screening
and their recommended colonoscopy screening intervals.
Among all colonoscopy strategies deemed efficient or
near-efficient in MISCAN-Colon, the optimal (most
effective) strategy meeting both the imposed benefit and
incremental burden-to-benefit criteria (ie, providing suffi-
cient LYG and having an ER< 50) was colonoscopy every
10 years from the ages of 50 to 75 years for white males
and females and colonoscopy every 10 years from the ages
of 45 to 75 years for black males and females (Table 3 and
Supporting Table 7). In SimCRC, colonoscopy screening
every 15 years from the ages of 45 to 75 years was model-
recommendable, regardless of race or sex. Among other
screening strategies with the same start and stop ages, rec-
ommended strategies by both models included FIT every
year and CTC every 5 years. From the stool-based screen-
ing modalities, HSgFOBT and FIT-DNA were not
model-recommendable because of their inefficiency from
higher false-positive rates and, in the case of FIT-DNA,
TABLE 3. Model-Recommendable Screening Strategies for 2 Scenarios of CRC Risk
Model
Test
Class
Scenario 1: Stable CRC Riska Scenario 2: Increased CRC Riskb
White
Females
Black
Females
White
Males
Black
Males
White
Females
Black
Females
White
Males
Black
Males
MISCAN COL 50-75, 10 45-75, 10 50-75, 10 45-75, 10 45-75, 10 45-75, 10 45-75, 5 45-75, 10
Stool FIT 50-75, 1 FIT 45-75, 1 FIT 50-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 — FIT 45-75, 1
SIG — — — — 45-75, 5 45-75, 5 — 45-75, 5
CTC 50-75, 5 45-75, 5 50-75, 5 45-75, 5 45-75, 5 45-75, 5 — 45-75, 5
SimCRC COL 45-75, 15 45-75, 15 45-75, 15 45-75, 15 45-75, 10 45-75, 10 45-75, 10 45-75, 10
Stool FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1 FIT 45-75, 1
SIG — — — — 45-75, 5 45-75, 5 45-75, 5 45-75, 5
CTC 45-75, 5 45-75, 5 45-75, 5 45-75, 5 45-75, 5 45-75, 5 45-75, 5 45-75, 5
Abbreviations: —, no model-recommendable strategy within this class; COL, colonoscopy; CRC, colorectal cancer; CTC, computed tomographic colonogra-
phy; FIT, fecal immunochemical testing; MISCAN, Microsimulation Screening Analysis; SIG, flexible sigmoidoscopy; SimCRC, Simulation Model of Colorectal
Cancer.
The numbers in each field of the table successively represent the recommended age to start screening, the recommended age to stop, and the recommended
interval, all in years. For the class of stool-based screening modalities, the model-recommendable modality is also included (ie, FIT).
a The risk within each age-, race-, and sex-specific demographic subgroup was assumed to have remained stable over time since the early screening period
in the United States (1975-1979 for SimCRC and 1990-1994 for MISCAN).
b The CRC risk was increased proportionally to observed trends in CRC incidence among adults younger than 40 years. Estimated incidence rate ratios were
1.80 to 1.90 for white females (range across models), 1.24 to 1.27 for black females, 2.07 to 2.13 for white males, and 1.41 to 1.56 for black males.
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also because of an unfavorable balance of burden and ben-
efit (a minimum of 63.3 additional colonoscopies per
LYG for annual FIT-DNA vs annual FIT). SIG was not
model-recommendable because of a failure to provide at
least 90% of the benefit of colonoscopy screening.
With assumed increased age-specific CRC risk, both
models recommended screening between the ages of 45
and 75 years for all 4 demographic subgroups, with colo-
noscopy recommended every 10 years, FIT annually, SIG
every 5 years, and CTC every 5 years, except for white
males, for whom MISCAN-Colon recommended only
colonoscopy every 5 years. SIG every 5 years was added to
the list of model-recommendable strategies for other pop-
ulation subgroups because of its higher comparative effec-
tiveness with more assumed distal tumors.
Sensitivity Analysis
Model recommendations were influenced by alternative
assumptions for test performance, the minimum accept-
able percentage of LYG for alternative strategies in com-
parison with colonoscopy screening, and a more stringent
acceptance threshold for the burden-to-benefit ratio (Sup-
porting Tables 8-11). Most notably, under worst-case per-
formance assumptions, MISCAN-Colon no longer
recommended CTC or SIG screening (Supporting Table
9); with a 75% acceptance threshold for LYG rather than
90% in comparison with colonoscopy screening, both
MISCAN-Colon and SimCRC included SIG in the set of
model-recommendable strategies, regardless of the sce-
nario for background risk (Supporting Table 10); and
with a burden-to-benefit threshold of a maximum of 40
additional colonoscopies per LYG rather than 50,
MISCAN-Colon no longer recommended earlier screen-
ing for blacks in the stable CRC risk scenario (Supporting
Table 11).
DISCUSSION
The results from this modeling study suggest that CRC
screening should be considered from the age of 45 years in
average-risk black Americans. The recommended age to
begin screening among whites varied across models, with
one model suggesting that screening should begin at the
age of 50 years in a scenario of stable age-specific CRC
risk and with the other suggesting that screening should
begin at the age of 45 years. If lifetime risk increases pro-
portionally to trends observed at younger ages, both mod-
els support recommending screening from the age of 45
years for all population subgroups. Within blacks and
whites, recommendable strategies generally did not differ
for men and women. Although men are at higher risk for
CRC than women, the higher potential benefit from
screening is partly offset by their lower life expectancy.
Model-recommendable strategies generally included colo-
noscopy screening every 10 or 15 years, FIT screening
every year, and CTC every 5 years through the age of 75
years. SIG was not consistently model-recommendable
because of its inability to meet the minimum benefit crite-
rion, and HSgFOBT and FIT-DNA were not recom-
mendable because of inefficiency.
Model-based recommendations were dependent on
assumptions for CRC risk. The models used in this study
were calibrated to data from a period in which guideline-
adherent screening was uncommon to avoid serious con-
tamination from either prevention of disease or an earlier
diagnosis. By making this assumption, the models implic-
itly assumed that the current underlying age-specific risk
of CRC in the absence of screening would be the same as
that observed in the prescreening era. However, SEER
data indicate that incidence has risen for every subsequent
generation born since the 1950s,34 and this suggests that
the projected underlying lifetime risk for current 40- to
50-year-olds may be elevated in comparison with earlier
birth cohorts. To reflect this uncertainty, we considered 2
scenarios for lifetime CRC risk: one in which age-, race-,
and sex-specific risks were assumed to remain stable over
time and another in which risks increased proportionally
to trends observed in young-onset cases. As we showed,
screening should be considered as early as the age of 45
years in both white and black men and women if the life-
time risk is increasing. This stems from converging risks
in white and black adults younger than 40 years26,37 and
is consistent with the recommendation in an accompany-
ing article by Peterse et al.10 The article by Peterse et al.
discusses the potential increase in disease risk in more
detail, including possible causal mechanisms other than
increased adenoma onset.
There were some discrepancies in screening recom-
mendations across the 2 models. Under the first scenario
of no increase in age-, race-, and sex-specific CRC risk
over time, MISCAN-Colon recommended screening for
black adults from the age of 45 years and for white adults
from the age of 50 years, both at 10-year intervals for colo-
noscopy. In contrast, SimCRC recommended both white
and black adults begin screening at the age of 45 years
with longer recommended colonoscopy intervals of 15
years. These differences reflect the differences in the dwell
time of adenomas (ie, the time from adenoma onset to
symptom-detected cancer in the absence of screening
among individuals with a CRC diagnosis)38 and were
observed in previous analyses for the USPSTF.13
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SimCRC has longer adenoma dwell times, and this sug-
gests that screening can be deferred longer after a negative
previous screening result. In addition, models were cali-
brated to different time periods from the early-screening
era (1975-1979 for SimCRC and 1990-1994 for MIS-
CAN-Colon). Although there may have been some
screening during the more recent period used to inform
MISCAN-Colon, this was to a large extent low-sensitivity
guaiac-based fecal occult blood testing with limited pre-
sumed influence on CRC incidence.39 CRC incidence
was similar in blacks and whites until the mid-1980s, but
it has since been higher among blacks than whites for
screening-eligible ages26; this may partly explain why
MISCAN-Colon recommended differential screening by
race. Although colonoscopy every 15 years between the
ages of 45 and 75 years was not considered efficient in
MISCAN-Colon for white adults in the stable-risk sce-
nario, the colonoscopy requirement and the predicted
number of LYG were close to those for colonoscopy every
10 years from the age of 50 to 75 years. This suggests that
the former strategy might be considered an option if uni-
formity in starting ages across demographic population
subgroups were desired. To date, younger recommended
start ages for screening black individuals by some organi-
zations6,7 have not led to higher screening rates among
blacks in comparison with whites aged 45 to 49 years
according to National Health Interview Survey data.40
Conversely, there is no evidence that race-specific recom-
mendations negatively affect screening uptake among
whites aged 50 to 54 years.
The cancer registry data used to inform the models
in this study did not allow the simulation of races/ethnici-
ties other than black and white. Although recommenda-
tions depend on patterns in risk across a person’s lifetime
and on other-cause mortality, we expect that model rec-
ommendations for other races/ethnicities except Alaskan
Natives would be closer to those for whites than those for
blacks because of the relatively similar observed CRC
mortality risks.1
To our knowledge, this is the first time that race and
sex differences have been formally considered for model-
based screening recommendations. The approach and
conclusions from the first stable age-specific risk scenario
in this study were similar to a study performed by
Lansdorp-Vogelaar et al.41 Our model-recommended
strategies differ from the 2016 USPSTF screening recom-
mendations, which suggested offering screening from the
ages of 50 to 75 years to all adults at average risk.8 Consis-
tent with 2009 American College of Gastroenterology6
and 2017 US Multi-Society Task Force guidelines,7 our
models recommend 45 years as the preferred starting age
for blacks. Previous modeling studies have suggested that
personalizing the age to stop screening may result in more
efficient use of resources and help to reduce potential
harms from screening.42 However, tailoring screening rec-
ommendations to different subgroups may complicate the
promotion of screening in the primary care setting, and
this may hamper guideline-consistent adherence. More
research is needed to assess the performance of personal-
ized screening programs before wide application in
practice.
There are some general limitations to the approach
of this study for selecting model-recommendable screen-
ing strategies. First, we predicted the potential benefit of
screening under the assumption of 100% adherence to
provide the best possible recommendation for patients
who adhere to screening. In practice, some forms of
screening may be less acceptable to people than others,43
and preferences may vary by setting, race, and sex and
over time.44-46 These preferences are an important deter-
minant of the success of any screening approach and
should be considered in practice. A test that is predicted to
have higher performance in the model in comparison
with other tests under the assumption of full adherence
may have lower population-based performance because of
lower acceptance. Second, to measure the burden of
screening, we used the required number of colonoscopies.
This ruled out a direct comparison of all strategies because
the burden from tests other than colonoscopy was not
explicitly considered. In practice, the potential burden
from the primary screening method, such as low-dose
radiation exposure in CTC, should also be considered
when one is recommending any of the evaluated strate-
gies. Finally, there are no objective or widely accepted
standards for the decision criteria applied in this study to
narrow down the set of potentially recommendable
screening strategies. We used similar acceptance thresh-
olds for the degree of efficiency (proximity to the efficient
frontier), minimum number of LYG, and maximum
number of colonoscopies per LYG as applied in analyses
performed for the USPSTF.13 As we showed in sensitivity
analyses, sigmoidoscopy may be added to recommended
screening modalities with a more relaxed benefit criterion
of at least 75% of LYG in comparison with colonoscopy-
based screening. Earlier ages to start screening may not be
acceptable with more stringent burden-to-benefit
thresholds.
In conclusion, using an established decision-analytic
modeling approach, we suggest that screening for CRC
should be considered between the ages 45 and 75 years for
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black adults in the United States and also for whites, par-
ticularly if lifetime risks have increased similarly to trends
observed under the age of 40 years. Colonoscopy every 10
to 15 years, FIT every year, and CTC every 5 years were
predicted to generate similar overall LYG with an accept-
able colonoscopy burden. Our findings differ from previ-
ous model recommendations for the USPSTF, in which
no distinction was made between blacks and whites, but
are consistent with recent recommendations by the US
Multi-Society Task Force.7 In recommending any partic-
ular screening strategy, policymakers and physicians
should consider patient preferences.
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